Literature DB >> 20540623

Comparative airway inflammatory response of normal volunteers to ozone and lipopolysaccharide challenge.

Michelle L Hernandez1, Bradford Harris, John C Lay, Philip A Bromberg, David Diaz-Sanchez, Robert B Devlin, Steven R Kleeberger, Neil E Alexis, David B Peden.   

Abstract

Ozone and lipopolysaccharide (LPS) are environmental pollutants with adverse health effects noted in both healthy and asthmatic individuals. The authors and others have shown that inhalation of ozone and LPS both induce airway neutrophilia. Based on these similarities, the authors tested the hypothesis that common biological factors determine response to these two different agents. Fifteen healthy, nonasthmatic volunteers underwent a 0.4 part per million ozone exposure for 2 h while performing intermittent moderate exercise. These same subjects underwent an inhaled LPS challenge with 20,000 LPS units of Clinical Center Reference LPS, with a minimum of 1 month separating these two challenge sessions. Induced sputum was obtained 24 h before and 4-6 h after each exposure session. Sputum was assessed for total and differential cell counts and expression of cell surface proteins as measured by flow cytometry. Sputum supernatants were assayed for cytokine concentration. Both ozone and LPS challenge augmented sputum neutrophils and subjects' responses were significantly correlated (R = .73) with each other. Ozone had greater overall influence on cell surface proteins by modifying both monocytes (CD14, human leukocyte antigen [HLA]-DR, CD11b) and macrophages (CD11b, HLA-DR) versus LPS where CD14 and HLA-DR were modified only on monocytes. However, LPS significantly increased interleukin (IL)-1beta, IL-6, and tumor necrosis factor (TNF)-alpha, with no significant increases seen after ozone challenge. Ozone and LPS exposure in healthy volunteers induce similar neutrophil responses in the airways; however, downstream activation of innate immune responses differ, suggesting that oxidant versus bacterial air pollutants may be mediated by different mechanisms.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20540623      PMCID: PMC3162474          DOI: 10.3109/08958371003610966

Source DB:  PubMed          Journal:  Inhal Toxicol        ISSN: 0895-8378            Impact factor:   2.724


  44 in total

1.  CD14-dependent airway neutrophil response to inhaled LPS: role of atopy.

Authors:  N Alexis; M Eldridge; W Reed; P Bromberg; D B Peden
Journal:  J Allergy Clin Immunol       Date:  2001-01       Impact factor: 10.793

Review 2.  TLR4 as the mammalian endotoxin sensor.

Authors:  B Beutler
Journal:  Curr Top Microbiol Immunol       Date:  2002       Impact factor: 4.291

3.  Low-dose airborne endotoxin exposure enhances bronchial responsiveness to inhaled allergen in atopic asthmatics.

Authors:  Brian Boehlecke; Milan Hazucha; Neil E Alexis; Robert Jacobs; Parker Reist; Philip A Bromberg; David B Peden
Journal:  J Allergy Clin Immunol       Date:  2003-12       Impact factor: 10.793

4.  Effects of glutathione S-transferase M1, maternal smoking during pregnancy, and environmental tobacco smoke on asthma and wheezing in children.

Authors:  Frank D Gilliland; Yu-Fen Li; Louis Dubeau; Kiros Berhane; Edward Avol; Rob McConnell; W James Gauderman; John M Peters
Journal:  Am J Respir Crit Care Med       Date:  2002-08-15       Impact factor: 21.405

5.  Effect of inhaled endotoxin on airway and circulating inflammatory cell phagocytosis and CD11b expression in atopic asthmatic subjects.

Authors:  Neil E Alexis; Marlowe W Eldridge; David B Peden
Journal:  J Allergy Clin Immunol       Date:  2003-08       Impact factor: 10.793

6.  Effects of ozone exposure on nuclear factor-kappaB activation and tumor necrosis factor-alpha expression in human nasal epithelial cells.

Authors:  B G Nichols; J S Woods; D L Luchtel; J Corral; J Q Koenig
Journal:  Toxicol Sci       Date:  2001-04       Impact factor: 4.849

7.  Blunting airway eosinophilic inflammation results in a decreased airway neutrophil response to inhaled LPS in patients with atopic asthma: a role for CD14.

Authors:  N E Alexis; D B Peden
Journal:  J Allergy Clin Immunol       Date:  2001-10       Impact factor: 10.793

8.  Allergen provocation augments endotoxin-induced nasal inflammation in subjects with atopic asthma.

Authors:  M W Eldridge; D B Peden
Journal:  J Allergy Clin Immunol       Date:  2000-03       Impact factor: 10.793

Review 9.  The biology of Toll-like receptors.

Authors:  T K Means; D T Golenbock; M J Fenton
Journal:  Cytokine Growth Factor Rev       Date:  2000-09       Impact factor: 7.638

10.  The glutathione-S-transferase Mu 1 null genotype modulates ozone-induced airway inflammation in human subjects.

Authors:  Neil E Alexis; Haibo Zhou; John C Lay; Bradford Harris; Michelle L Hernandez; Tsui-Shan Lu; Philip A Bromberg; David Diaz-Sanchez; Robert B Devlin; Steven R Kleeberger; David B Peden
Journal:  J Allergy Clin Immunol       Date:  2009-12       Impact factor: 10.793

View more
  25 in total

1.  Flow cytometry of sputum: assessing inflammation and immune response elements in the bronchial airways.

Authors:  John C Lay; David B Peden; Neil E Alexis
Journal:  Inhal Toxicol       Date:  2011-06       Impact factor: 2.724

Review 2.  The effect of environmental oxidative stress on airway inflammation.

Authors:  Amy Auerbach; Michelle L Hernandez
Journal:  Curr Opin Allergy Clin Immunol       Date:  2012-04

3.  Atopic asthmatic patients have reduced airway inflammatory cell recruitment after inhaled endotoxin challenge compared with healthy volunteers.

Authors:  Michelle L Hernandez; Margaret Herbst; John C Lay; Neil E Alexis; Willie June Brickey; Jenny P Y Ting; Haibo Zhou; David B Peden
Journal:  J Allergy Clin Immunol       Date:  2012-07-04       Impact factor: 10.793

4.  Nrf2 is essential for the anti-inflammatory effect of carbon monoxide in LPS-induced inflammation.

Authors:  SiYuan Qin; RongHui Du; ShaSha Yin; XinFeng Liu; GeLin Xu; Wangsen Cao
Journal:  Inflamm Res       Date:  2015-06-07       Impact factor: 4.575

5.  Gamma tocopherol-enriched supplement reduces sputum eosinophilia and endotoxin-induced sputum neutrophilia in volunteers with asthma.

Authors:  Allison J Burbank; Charity G Duran; Yinghao Pan; Patricia Burns; Susan Jones; Qing Jiang; Chao Yang; Sha'Leema Jenkins; Heather Wells; Neil Alexis; Mehmet Kesimer; William D Bennett; Haibo Zhou; David B Peden; Michelle L Hernandez
Journal:  J Allergy Clin Immunol       Date:  2017-07-20       Impact factor: 10.793

6.  Effect of inhaled endotoxin on mucociliary clearance and airway inflammation in mild smokers and nonsmokers.

Authors:  William D Bennett; Neil E Alexis; Martha Almond; Margaret Herbst; Kirby L Zeman; David B Peden
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2014-12       Impact factor: 2.849

7.  Enhancement of systemic and sputum granulocyte response to inhaled endotoxin in people with the GSTM1 null genotype.

Authors:  Madeline A Dillon; Bradford Harris; Michelle L Hernandez; Baiming Zou; William Reed; Philip A Bromberg; Robert B Devlin; David Diaz-Sanchez; Steven Kleeberger; Haibo Zhou; John C Lay; Neil E Alexis; David B Peden
Journal:  Occup Environ Med       Date:  2011-03-25       Impact factor: 4.402

8.  GSTM1 modulation of IL-8 expression in human bronchial epithelial cells exposed to ozone.

Authors:  Weidong Wu; Vinod Doreswamy; David Diaz-Sanchez; James M Samet; Matt Kesic; Lisa Dailey; Wenli Zhang; Ilona Jaspers; David B Peden
Journal:  Free Radic Biol Med       Date:  2011-05-14       Impact factor: 7.376

Review 9.  Particulate matter containing environmentally persistent free radicals and adverse infant respiratory health effects: a review.

Authors:  Jordy Saravia; Greg I Lee; Slawo Lomnicki; Barry Dellinger; Stephania A Cormier
Journal:  J Biochem Mol Toxicol       Date:  2012-12-20       Impact factor: 3.642

10.  Interaction with epithelial cells modifies airway macrophage response to ozone.

Authors:  Rebecca N Bauer; Loretta Müller; Luisa E Brighton; Kelly E Duncan; Ilona Jaspers
Journal:  Am J Respir Cell Mol Biol       Date:  2015-03       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.